Sims Bio has implemented a third-party allocation of new shares with Japan Genetics as the underwriter and has begun the development of a "desktop cell automatic culture device" equipped with machine learning capabilities.

Simus Bio Co., Ltd. (Nagoya City), which is engaged in the manufacturing and sales of cell culture equipment and regenerative medicine support for medical facilities, has raised 30 million yen through a third-party allocation of shares with Japan Genetics Co., Ltd. (Bunkyo City, Tokyo), a trading company specializing in life science research, as the underwriter. Going forward, we will strengthen the sales of our cell mass large-scale culture and differentiation induction microplate "TASCL" to research institutions both domestically and internationally through Japan Genetics. Additionally, we will begin the development of a "desktop automatic cell culture device" equipped with machine learning capabilities for cell culture based on TASCL, taking this capital increase as an opportunity. We will also seek further fundraising and technological collaboration from other companies in the future.


Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration
Related Links
Website of Simus Bio Co., Ltd.